ClinicaliQ Trial Snapshot
- A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer — Recruiting • Phase I • Oncology • NCT07206225.
- Drug being tested: PF-08052667 is a novel investigational medicine being evaluated as monotherapy or in combination with BCG (standard intravesical immunotherapy) and/or sasanlimab (an immunotherapy agent) for bladder cancer treatment.
- Patient eligibility: The trial recruits adults with bladder cancer; specific eligibility criteria (disease stage, prior treatment history, performance status) would be detailed in the full protocol but typically include both treatment-Phase Iïve and previously treated patients.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to learn how a new medicine called PF-08052667 works when used by itself or together with another medicine called Bacillus Calmette Guerin (BCG), and/or a medicine called sasanlimab. This study is for adults who have a type of bladder cancer that hasn't spread into the muscle layer of the bladder but is more likely to come back or grow. It includes people whose cancer has come back or hasn't gone away after receiving standard treatments like BCG. It may also include people who, based…
Eligibility Snapshot
- : 1. 18 years of age or older (or the minimum age of consent per local regulations) 2. Histological diagnosis of high-risk, non-muscle invasive urothelial carcinoma of the bladder defined according to the WHO grading system as carcinoma in situ (CIS), with or without concurrent T1/Ta papillary disease. Note: High-grade T1/Ta papillary disease, in the absence of CIS, may be eligible for certain cohorts in Part 2 and 3 3. BCG unresponsive and BCG-exposed cohorts should have persistent or recurrent disease after receiving at least 5 out of 6 doses of the BCG induction therapy. 4. Have refused or are ineligible or not appropriate for radical cystectomy 5. Tissue Requirement: Available tumor tissue within the last 6 months. On-treatment tumor biopsy is optional, unless mandated based on emerging data, or participating in the Biomarker Cohort, or for disease assessment 6. ECOG PS 0 or 1
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.